Navidea Biopharmaceuticals announced today that technetium-99m tilmanocept (Lymphoseek) has been approved by the European Commission for the detection of sentinel lymph node involvement in primary breast cancer, melanoma and localized squamous cell carcinoma.

When four-state Mercy broke ground on a four-story, 120,000-square-foot virtual-care center on a patch of green in Chesterfield, Mo., last spring, the blueprint represented a bold and visionary step into American healthcare’s digital future, as the center may be the first of its kind anywhere in the world. The organization estimates that the center will manage more than three million telehealth visits in the first five years following its scheduled 2015 opening.

Protea Biosciences, a biomedical company based in Morgantown, W. Va, announced yesterday that third quarter financial results amounted to $517,569, the highest revenue on record for the company. However net losses are still steep at more than $4.6 million for the third quarter.

Even mild cases of dental disease could have long-term effects on amyloid plaque development and brain health, according to a neuroimaging study published online Nov. 5 in Neurobiology of Aging.

Two novel technetium-99m agents, when used with SPECT or planar imaging, have been found to effectively target prostate specific membrane antigen (PSMA) in advanced prostate cancer within bone, lymph nodes and soft tissues, according to a study published in the November issue of the Journal of Nuclear Medicine.

Infections related to heart valve prosthesis are usually diagnosed with echocardiography, but it can miss key areas of infection. It is here that FDG PET or leukocute scintigraphy can step in, but a recent comparison study of the two nuclear medicine procedures published Nov. 13 in the Journal of Nuclear Medicine shows that FDG PET may be the best option.

The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) has agreed to provide supplemental funding for NorthStar Medical Radioisotopes’ medical isotope production venture.

The Saskatoon, Canada-based Canadian Light Source has reached a major benchmark in the company’s Medical Isotope Project by shipping the first major supply of isotopes, the company announced Friday. Health Canada has yet to approve it, but, with further testing, this technology could begin supplying medical isotopes to medical facilities in the region by 2016.